{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:26:21Z","timestamp":1787286381251,"version":"build-2736575974"},"reference-count":59,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in older adults, and in Mexico\u2019s rapidly growing older-adult population it may place increasing pressure on hospital-based care; however, Mexico-specific evidence to inform adult RSV immunization policy remains limited. This study estimated the long-term clinical and economic burden of medically attended RSV among adults aged 60\u201399 years in Mexico and evaluated the health impact and cost-effectiveness of a year-round RSVpreF vaccination program. Methods: A population-based Markov cohort model compared the RSVpreF vaccination with no vaccination in a hypothetical Mexican cohort aged 60\u201399 years over a lifetime horizon. Outcomes included RSV-related hospitalizations, emergency department (ED) and physician office (PO) encounters, in-hospital deaths, life-years (LYs), and quality-adjusted life-years (QALYs). Analyses were conducted from Mexican healthcare system and societal perspectives in 2025 Mexican pesos (MXN$) and US dollars (US$), with costs and outcomes discounted at 5% annually. One-way and probabilistic sensitivity analyses and scenario analyses assessed the robustness of the findings. Results: With 58% uptake, RSVpreF reduced hospitalizations by 187,825, ED encounters by 178,278, PO encounters by 465,976, and RSV-related deaths by 15,384. In the first 5 years, hospitalizations, ED encounters, and deaths declined by 31% each, and PO encounters by 14%. Over the lifetime horizon, vaccination generated an additional 96,227 discounted LYs and 71,526 discounted QALYs, while avoiding MXN$ 19,484 million (US$ 1061 million) in direct medical costs and MXN$ 3324 million (US$ 181 million) in indirect costs. Conclusions: Year-round RSVpreF vaccination in Mexico among adults aged 60\u201399 years could substantially reduce medically attended RSV cases and RSV-related mortality and is projected to be cost-effective, thereby supporting the adoption of preventive strategies to address the growing clinical and economic burden of RSV in Mexico\u2019s aging population.<\/jats:p>","DOI":"10.3390\/vaccines14080713","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:58:23Z","timestamp":1787126303000},"page":"713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis of Older Adult Vaccination with the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico"],"prefix":"10.3390","volume":"14","author":[{"given":"Veronica","family":"Guajardo","sequence":"first","affiliation":[{"name":"Pfizer, Mexico City 05120, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shajarizadeh","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc., Vancouver, BC V5Y 1K2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishu","family":"Gaind","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc., Vancouver, BC V5Y 1K2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Ivkovic","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc., Vancouver, BC V5Y 1K2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengina","family":"Kefalogianni","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Tadworth, Surrey KT20 7NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mendes","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Tadworth, Surrey KT20 7NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1017\/S0950268820000400","article-title":"The burden of respiratory syncytial virus in adults: A systematic review and meta-analysis","volume":"148","author":"Yerramalla","year":"2020","journal-title":"Epidemiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ciapponi, A., Palermo, M.C., Sandoval, M.M., Baumeister, E., Ruvinsky, S., Ulloa-Gutierrez, R., Stegelmann, K., Ruesjas, S.A., Cantos, J., and LaRotta, J. (2024). Respiratory syncytial virus disease burden in children and adults from Latin America: A systematic review and meta-analysis. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1377968"},{"key":"ref_3","unstructured":"CONAPO (2025, October 20). General Secretariat of the National Population Council, Available online: https:\/\/www.datos.gob.mx\/dataset\/proyecciones-de-poblacion."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez-Ram\u00edrez, L., Sosa-Jurado, F., D\u00edaz-Sampayo, G., Solis-Tejeda, I., Rodr\u00edguez-P\u00e9rez, F., Pelayo, R., Santos-L\u00f3pez, G., and Cortes-Hernandez, P. (2023). Age and Comorbidities as Risk Factors for Severe COVID-19 in Mexico, before, during and after Massive Vaccination. Vaccines, 11.","DOI":"10.3390\/vaccines11111676"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40266-015-0258-9","article-title":"Respiratory syncytial virus infection in older adults: An under-recognized problem","volume":"32","author":"Branche","year":"2015","journal-title":"Drugs Aging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s41030-024-00253-3","article-title":"Understanding the Burden of Respiratory Syncytial Virus in Older Adults in Latin America: An Expert Perspective on Knowledge Gaps","volume":"10","author":"Correa","year":"2024","journal-title":"Pulm. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40121-023-00802-4","article-title":"Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data","volume":"12","author":"Rozenbaum","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103292","DOI":"10.1016\/j.eclinm.2025.103292","article-title":"Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: Application of the Global Burden of Disease framework","volume":"85","author":"Burkart","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"220105","DOI":"10.1183\/16000617.0105-2022","article-title":"Burden of respiratory syncytial virus infection in older and high-risk adults: A systematic review and meta-analysis of the evidence from developed countries","volume":"31","author":"Martin","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Amand, C., Tong, S., Kieffer, A., and Kyaw, M.H. (2018). Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: A claims database analysis. BMC Health Serv. Res., 18.","DOI":"10.1186\/s12913-018-3066-1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ofae097","DOI":"10.1093\/ofid\/ofae097","article-title":"Attributable Cost of Adult Respiratory Syncytial Virus Illness Beyond the Acute Phase","volume":"11","author":"Averin","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mendes, D., Lucas, J., Quinones, E., Li, K., Fievez, S., Lade, C., Di Virgilio, R., Lopez-Ibanez de Aldecoa, A., Piercy, J., and Holbrook, T. (2026). Resource use and economic burden of respiratory syncytial virus among older adults in real-world clinical practice across five European countries. Front. Public Health, 14.","DOI":"10.3389\/fpubh.2026.1773556"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sato, R., Judy, J., Yacisin, K., Begier, E., Sardana, P., Agrawal, N., Goswami, A., and Sharma, M. (2024). Immediate post-discharge care among US adults hospitalized with respiratory syncytial virus infection. BMC Pulm. Med., 24.","DOI":"10.1186\/s12890-024-03251-y"},{"key":"ref_15","unstructured":"COFEPRIS (2025, October 20). Cofepris Authorizes Vaccines Against Respiratory Syncytial Virus (RSV) for Use in Pregnant Women and Older Adults [Comisi\u00f3n Federal para la Protecci\u00f3n Contra Riesgos Sanitarios], Available online: https:\/\/www.gob.mx\/cofepris\/es\/articulos\/cofepris-autoriza-vacunas-contra-virus-sincicial-respiratorio-vsr-para-aplicar-a-mujeres-embarazadas-y-adultos-mayores-386366?idiom=es."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","first-page":"101520","article-title":"Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: A retrospective test-negative case control study","volume":"60","author":"Tartof","year":"2026","journal-title":"Lancet Reg. Health Am."},{"key":"ref_18","unstructured":"Tartof, S.Y. (2025, January 19\u201322). Vaccine Effectiveness of Abrysvo against Respiratory Syncytial Virus-related Lower Respiratory Tract Disease Hospitalizations and Emergency Department Admissions over Two RSV Seasons. Proceedings of the IDWeek 2025, Atlanta, GA, USA."},{"key":"ref_19","unstructured":"ENSANUT (2025, October 20). National Continuous Health and Nutrition Survey [Encuesta Nacional de Salud y Nutrici\u00f3n], Available online: https:\/\/ensanut.insp.mx\/encuestas\/ensanutcontinua2023\/doctos\/informes\/ensanut_23_112024.pdf."},{"key":"ref_20","unstructured":"Public Health Agency of Canada (2026, July 29). Summary of NACI Statement of April 10, 2026: Updated Guidance on Respiratory Syncytial Virus (RSV) Vaccines for Older Adults and for Adults at High Risk of Severe RSV Disease, Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-summary-updated-guidance-respiratory-syncytial-virus-vaccines-older-adults-high-risk-severe-rsv-disease.html."},{"key":"ref_21","unstructured":"Centers for Disease Control and Prevention (2026, July 29). RSV Vaccine Guidance for Adults, Available online: https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/adults.html."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s41999-026-01440-y","article-title":"A comparison of the national European guidelines: RSV vaccination in older adults","volume":"17","author":"Desrumaux","year":"2026","journal-title":"Eur. Geriatr. Med."},{"key":"ref_23","unstructured":"Ministry of Health of the Republic of Panama [Ministerio de Salud de la Rep\u00fablica de Panam\u00e1] (2026, July 29). The Vaccine Against Respiratory Syncytial Virus Arrives in Panama [Llega a Panam\u00e1 la Vacuna Contra el Virus Sincitial Respiratorio], Available online: https:\/\/www.minsa.gob.pa\/noticia\/llega-panama-la-vacuna-contra-el-virus-sincitial-respiratorio."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2024.2436183","article-title":"Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany","volume":"24","author":"Averin","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gourzoulidis, G., Tzanetakos, C., Solakidi, A., Markatis, E., Detsis, M., Mendes, D., and Barmpouni, M. (2024). Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece. Vaccines, 12.","DOI":"10.3390\/vaccines12111232"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s40121-025-01177-4","article-title":"Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older","volume":"14","author":"Komiya","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"ofae631.2508","DOI":"10.1093\/ofid\/ofae631.2508","article-title":"P-2357. Respiratory Syncytial Virus (RSV) Disease Burden among Adults in Primary Care Settings in High-income Countries: A Systematic Review and Modelling Study","volume":"12","author":"Li","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40121-023-00904-z","article-title":"Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile","volume":"13","author":"Weycker","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_29","unstructured":"National Institute of Statistics and Geography [Instituto Nacional de Estad\u00edstica y Geograf\u00eda] (2025, October 20). General Mortality [Mortalidad General], Available online: https:\/\/www.inegi.org.mx\/sistemas\/olap\/registros\/vitales\/mortalidad\/tabulados\/def03.asp?t=02&c=11805."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"106476","DOI":"10.1016\/j.rmed.2021.106476","article-title":"Mortality and readmission in the year following hospitalization for pneumonia among US adults","volume":"185","author":"Averin","year":"2021","journal-title":"Respir. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/21645515.2018.1516491","article-title":"Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico","volume":"15","author":"Wasserman","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","article-title":"Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available","volume":"14","author":"Ara","year":"2011","journal-title":"Value Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","article-title":"Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease","volume":"22","author":"Mendes","year":"2022","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/irv.12903","article-title":"Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact Questionnaire","volume":"16","author":"Falsey","year":"2022","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1093\/infdis\/jiac069","article-title":"Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults","volume":"226","author":"Mao","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_36","unstructured":"Mexican Social Security Institute [Instituto Mexicano del Seguro Social] (2025, October 20). Unit Costs [Costos Unitarios], Available online: https:\/\/www.diariooficial.gob.mx\/nota_detalle.php?codigo=5745162&fecha=13\/12\/2024#gsc.tab=0."},{"key":"ref_37","unstructured":"Hern\u00e1ndez Balboa, C.L. (2025, October 20). Clinical Characterization of Patients and Genomic Description of Respiratory Syncytial Virus in the 2023\u20132024 Winter Season [Caracterizaci\u00f3n Cl\u00ednica de Pacientes y Descripci\u00f3n Gen\u00f3mica de Virus Sincitial Respiratorio en la Temporada Invernal 2023\u20132024]. Available online: http:\/\/eprints.uanl.mx\/28921\/7\/28921.pdf."},{"key":"ref_38","unstructured":"World Bank (2025, October 20). GDP per Capita (Current US$). Available online: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD."},{"key":"ref_39","unstructured":"World Bank (2025, October 20). GDP per Capita (Current LCU). Available online: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CN."},{"key":"ref_40","unstructured":"World Health Organization (2024, October 10). Macroeconomics and Health: Investing in Health for Economic Development: Executive Summary\/Report of the Commission on Macroeconomics and Health. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/42463\/a74868.pdf?sequence=1&isAllowed=y."},{"key":"ref_41","unstructured":"National Institute of Statistics and Geography [Instituto Nacional de Estad\u00edstica y Geograf\u00eda] (2025, October 20). National Occupation and Employment Survey, Population Aged 15 Years and Over [Encuesta Nacional de Ocupaci\u00f3n y Empleo (ENOE), Poblaci\u00f3n de 15 A\u00f1os y M\u00e1s de Edad], Available online: https:\/\/en.www.inegi.org.mx\/programas\/enoe\/15ymas\/#tabular_data."},{"key":"ref_42","unstructured":"National Institute of Statistics and Geography [Instituto Nacional de Estad\u00edstica y Geograf\u00eda] (2025, October 20). National Household Income and Expenditure Survey. 2024 New Series [Encuesta Nacional de Ingresos y Gastos de los Hogares (ENIGH). 2024 Nueva Serie], Available online: https:\/\/www.inegi.org.mx\/contenidos\/saladeprensa\/boletines\/2025\/enigh\/ENIGH2024_RR.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3201\/eid2801.211357","article-title":"Use of Private Sector Workforce Respiratory Disease Short-Term Disability Claims to Assess SARS-CoV-2, Mexico, 2020","volume":"28","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_44","unstructured":"Xe (2025, October 20). International Money Transfers and Global Currency Conversions. Available online: https:\/\/www.xe.com\/en-ca\/."},{"key":"ref_45","unstructured":"Government of Mexico [Gobierno de Mexico] (2025, October 20). Guide for Conducting Economic Evaluation Studies for the Update of the National Compendium of Health Supplies [Gu\u00eda para la Conducci\u00f3n de Estudios de Evaluaci\u00f3n Econ\u00f3mica para la Actualizaci\u00f3n del Compendio Nacional de Insumos para la Salud], Available online: https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/920130\/GCEEE_Enero_2023.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jacc.2018.02.013","article-title":"Respiratory Syncytial Virus and Associations with Cardiovascular Disease in Adults","volume":"71","author":"Ivey","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1093\/cid\/ciaf310","article-title":"Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized with RSV","volume":"82","author":"Sudnik","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1473-3099(25)00546-8","article-title":"Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75-79 years in England: A multicentre, test-negative, case-control study","volume":"26","author":"Symes","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/jama.2025.15896","article-title":"RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons","volume":"334","author":"Surie","year":"2025","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hec.1534","article-title":"Cost-effectiveness acceptability curves--caveats quantified","volume":"19","author":"Jakubczyk","year":"2010","journal-title":"Health Econ."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/infdis\/jiab118","article-title":"Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom","volume":"226","author":"Zeevat","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciad658","article-title":"Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States","volume":"78","author":"Moghadas","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.vaccine.2024.02.041","article-title":"Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study","volume":"42","author":"Shoukat","year":"2024","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wang, Y., Fekadu, G., and You, J.H.S. (2023). Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong. Vaccines, 11.","DOI":"10.3390\/vaccines11101605"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.12688\/gatesopenres.13201.1","article-title":"What next after GDP-based cost-effectiveness thresholds?","volume":"4","author":"Chi","year":"2020","journal-title":"Gates Open Res."},{"key":"ref_56","unstructured":"World Health Organization (2026, August 01). Macroeconomics and Health: Investing in Health for Economic Development. Available online: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/4ca4b21d-2c29-4b55-972c-7df9b5258401\/content."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Heyerdahl-Viau, I., Prado-Galbarro, F.J., Avila-Rios, S., Rosas-Becerril, O.A., Cruz-Flores, R.A., Sanchez-Piedra, C., and Martinez-Nunez, J.M. (2025). Adherence and Cost-Utility Analysis of Antiretroviral Treatment in People Living with HIV in a Specialized Clinic in Mexico City. Pharmacy, 13.","DOI":"10.3390\/pharmacy13030076"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Shim, E. (2017). Cost-effectiveness of dengue vaccination in Yucatan, Mexico using a dynamic dengue transmission model. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175020"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"108336","DOI":"10.1016\/j.diabres.2020.108336","article-title":"Cost-effectiveness analysis of a multidisciplinary health-care model for patients with type-2 diabetes implemented in the public sector in Mexico: A quasi-experimental, retrospective evaluation","volume":"167","year":"2020","journal-title":"Diabetes Res. Clin. Pract."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:18:22Z","timestamp":1787285902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["vaccines14080713"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14080713","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}